Hematologic Cancers

Imagine you’ve been feeling more tired lately, but you think, who isn’t? You work long hours at the office and at home. The fatigue becomes worse. After a battery of blood tests, the practitioner tells you the results. Read More ›

Several new drugs for the treatment of chronic lymphocytic leukemia (CLL) are considered major advances: 2 have been approved and 2 are under review by the US Food and Drug Administration (FDA). Read More ›

The optimal dosing of pomalidomide in the treatment of multiple myeloma has not been established. Yale University investigators compared continuous and intermittent dosing regimens, and while the intermittent schedule was associated with more toxicity, they concluded that it is preferable... Read More ›

For patients with non-Hodgkin lymphoma (NHL) receiving chemotherapy, primary prophylaxis against febrile neutropenia (FN) can safely be administered on the same treatment day, if necessary, according to a review of patients from the Cleveland Clinic, presented at the 2013 American Society of Hematology annual meeting. Read More ›

As the second leading cause of cancer-related deaths among men in the United States, prostate cancer is expected to cause approximately 29,720 deaths during 2013. In recognition of National Prostate Cancer Awareness Month, let’s examine these prostate cancer statistics. Read More ›

Advances in the understanding of the biology of multiple myeloma (MM) and the identification of new drugs have resulted in improved management of MM, including patients who are refractory to proteasome inhibitors and immunomodulatory agents. Read More ›


Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations. Read More ›

Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors. Read More ›

At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL). Read More ›

Page 6 of 10


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: